Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY). Hangzhou Tigermed Consulting Co. , Ltd is a contract research organization (CRO) providing comprehensive services to the pharmaceutical and biotech industries. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) Healthcare & Pipeline Overview
Hangzhou Tigermed Consulting Co., Ltd is a leading contract research organization offering integrated clinical trial solutions and laboratory services. With a global presence and a focus on the Chinese market, Tigermed supports pharmaceutical and biotech companies in drug development, leveraging its comprehensive service portfolio and established industry expertise.
Investment Thesis
Hangzhou Tigermed Consulting Co., Ltd presents an investment opportunity within the growing CRO market, driven by increasing pharmaceutical R&D spending and the outsourcing trend. Tigermed's comprehensive service offerings and strong presence in the Chinese market are key value drivers. The company's financial profile includes a market cap of $3.44 billion, a profit margin of 9.3%, and a gross margin of 26.5%. A debt-to-equity ratio of 7.07 indicates a conservative capital structure. Key catalysts include expansion into new therapeutic areas and geographic regions. Potential risks include regulatory changes in the pharmaceutical industry and increased competition from other CROs. Investors should monitor revenue growth, margin expansion, and the company's ability to maintain its market share in China and internationally.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $3.44 billion reflects Tigermed's established position in the CRO market.
- Profit margin of 9.3% indicates profitability within the competitive CRO landscape.
- Gross margin of 26.5% demonstrates the company's ability to manage service delivery costs effectively.
- Debt-to-equity ratio of 7.07 suggests a relatively low level of financial leverage.
- Presence in both China and international markets provides diversification and access to different growth opportunities.
Competitors & Peers
Strengths
- Comprehensive service offerings spanning preclinical to post-marketing.
- Strong presence in the Chinese market.
- Experienced management team with expertise in drug development.
- Global reach and ability to conduct multi-region clinical trials.
Weaknesses
- Reliance on the pharmaceutical and biotech industries.
- Exposure to regulatory changes and compliance risks.
- Competition from larger CROs with greater resources.
- Dependence on key personnel and expertise.
Catalysts
- Potential partnerships with major pharmaceutical companies could drive revenue growth.
- Expansion of service offerings into new therapeutic areas.
- Increasing adoption of decentralized clinical trials.
- Geographic expansion into emerging markets.
- Leveraging data analytics and AI to improve clinical trial efficiency.
Risks
- Economic downturns could reduce pharmaceutical R&D spending.
- Increased competition from other CROs could erode market share.
- Changes in regulatory requirements could increase compliance costs.
- Data breaches and cybersecurity risks could damage the company's reputation.
- Reliance on the Chinese market exposes the company to political and economic risks.
Growth Opportunities
- Expansion into new therapeutic areas represents a significant growth opportunity for Tigermed. By diversifying its expertise beyond its current focus, the company can attract a broader range of clients and projects. The global market for specialized CRO services in areas like oncology and immunology is expanding rapidly, presenting opportunities for Tigermed to leverage its existing infrastructure and expertise to capture additional market share. Timeline: Ongoing.
- Geographic expansion, particularly in emerging markets, offers another avenue for growth. As pharmaceutical R&D spending increases in regions like Southeast Asia and Latin America, Tigermed can establish a presence and offer its services to local and international companies. This expansion can be achieved through strategic partnerships, acquisitions, or organic growth. Timeline: Ongoing.
- The increasing adoption of decentralized clinical trials (DCTs) presents a growth opportunity for Tigermed. DCTs leverage technology to conduct clinical trials remotely, improving patient access and reducing costs. Tigermed can invest in its DCT capabilities, including telemedicine platforms, remote monitoring devices, and data analytics tools, to capitalize on this trend. The DCT market is projected to grow significantly in the coming years. Timeline: Ongoing.
- Offering specialized services in areas like medical device and in vitro diagnostics (IVD) development can drive growth. As the medical device and IVD industries continue to innovate, there is a growing need for CROs with expertise in these areas. Tigermed can expand its service offerings to include regulatory consulting, clinical trial management, and market access support for medical devices and IVDs. Timeline: Ongoing.
- Leveraging data analytics and artificial intelligence (AI) to improve clinical trial efficiency and outcomes represents a growth opportunity. Tigermed can invest in data analytics platforms and AI algorithms to optimize trial design, patient recruitment, and data analysis. These technologies can help to reduce costs, accelerate timelines, and improve the success rates of clinical trials. Timeline: Ongoing.
Opportunities
- Expansion into new therapeutic areas and geographic regions.
- Increasing adoption of decentralized clinical trials.
- Growth in the medical device and IVD industries.
- Leveraging data analytics and AI to improve clinical trial efficiency.
Threats
- Economic downturns and reduced pharmaceutical R&D spending.
- Increased competition from other CROs.
- Changes in regulatory requirements and drug approval processes.
- Data breaches and cybersecurity risks.
Competitive Advantages
- Established presence in the Chinese market provides a competitive advantage.
- Comprehensive service offerings create switching costs for clients.
- Expertise in regulatory affairs and clinical trial management.
- Strong relationships with pharmaceutical and biotech companies.
- Global reach allows for participation in multi-region clinical trials.
About HNGZY
Hangzhou Tigermed Consulting Co., Ltd, established in 2004 and headquartered in Hangzhou, China, is a comprehensive contract research organization (CRO) providing a wide array of services to the pharmaceutical, biotechnology, and medical device industries. The company's evolution has been marked by its expansion from a primarily China-focused operation to a global service provider. Tigermed offers end-to-end solutions spanning preclinical development, clinical trial management, and post-marketing clinical research. Its service portfolio includes preclinical services such as medicinal chemistry, compound screening, and toxicology studies. In clinical development, Tigermed provides medical writing, clinical monitoring, regulatory affairs support, data management, and statistical analysis. The company also specializes in decentralized clinical trials, site management, and multi-region clinical trials. Tigermed further offers specialized services like medical imaging, pharmacovigilance, medical translation, and quality assurance. Its laboratory services include central laboratories, functional services, and bioequivalence studies. Tigermed's geographic reach extends beyond China, serving clients internationally and positioning itself as a key partner for global clinical trials.
What They Do
- Provides preclinical development services, including medicinal chemistry and toxicology studies.
- Offers clinical development services, such as medical writing and clinical monitoring.
- Manages regulatory affairs, data management, and statistical analysis for clinical trials.
- Conducts decentralized clinical trials and site management.
- Provides medical imaging, pharmacovigilance, and medical translation services.
- Offers quality assurance, GMP, and medical device consulting.
- Operates central laboratories and functional services.
- Provides post-marketing clinical research solutions.
Business Model
- Generates revenue by providing contract research services to pharmaceutical, biotech, and medical device companies.
- Charges fees for preclinical development, clinical trial management, and post-marketing research services.
- Offers a comprehensive suite of services, allowing clients to outsource multiple aspects of drug development.
- Operates on a project-based model, with revenue tied to the successful completion of milestones.
Industry Context
Hangzhou Tigermed Consulting Co., Ltd operates within the global contract research organization (CRO) market, which is experiencing growth driven by increasing pharmaceutical R&D spending and the trend of outsourcing clinical trials. The CRO market is competitive, with companies like IQVIA and Laboratory Corporation of America (LH) offering similar services. Tigermed's focus on the Chinese market provides a strategic advantage, given the growth of the pharmaceutical industry in China. The company's ability to offer a comprehensive suite of services, from preclinical to post-marketing, positions it as a valuable partner for pharmaceutical and biotech companies.
Key Customers
- Pharmaceutical companies seeking to outsource drug development activities.
- Biotechnology companies developing new therapies and diagnostics.
- Medical device companies requiring clinical trial support.
- Academic institutions conducting clinical research.
- Government agencies involved in drug regulation and approval.
Financials
Chart & Info
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) stock price: Price data unavailable
Latest News
No recent news available for HNGZY.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HNGZY.
Price Targets
Wall Street price target analysis for HNGZY.
MoonshotScore
What does this score mean?
The MoonshotScore rates HNGZY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
HNGZY OTC Market Information
The OTC Other tier represents the lowest of the OTC Markets tiers. Companies in this tier often have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. These companies may not meet the minimum requirements for listing on higher tiers like OTCQB or OTCQX, which demand regular financial reporting and adherence to corporate governance standards. Investing in OTC Other stocks carries a higher degree of risk due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in HNGZY.
- Lower trading volume and wider bid-ask spreads can lead to price volatility.
- OTC stocks are subject to less regulatory oversight than exchange-listed stocks.
- The OTC Other tier carries a higher risk of fraud and manipulation.
- Lack of analyst coverage and institutional interest can limit liquidity.
- Verify the company's registration and compliance with regulatory requirements.
- Review any available financial statements and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Be aware of the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 2004.
- It provides services to pharmaceutical and biotech companies.
- It has a global reach and conducts multi-region clinical trials.
Common Questions About HNGZY (Healthcare)
What does Hangzhou Tigermed Consulting Co., Ltd do?
Hangzhou Tigermed Consulting Co., Ltd is a contract research organization (CRO) that provides comprehensive services to pharmaceutical, biotech, and medical device companies. The company supports drug development from preclinical stages through post-market clinical research. Its services include preclinical development, clinical trial management, regulatory affairs, data management, and post-marketing studies. Tigermed operates both in China and internationally, offering a range of solutions to help clients bring new products to market efficiently and effectively. The company's focus on the Chinese market provides a strategic advantage, given the growth of the pharmaceutical industry in China.
What do analysts say about HNGZY stock?
As of 2026-03-16, there is no available analyst consensus for HNGZY stock due to its OTC listing and limited coverage. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors. Key valuation metrics include market capitalization, profit margin, and gross margin. Growth considerations include expansion into new therapeutic areas, geographic regions, and service offerings. Investors should also be aware of the risks associated with investing in OTC stocks, such as limited liquidity and regulatory oversight. Further AI analysis is pending.
What are the main risks for HNGZY?
The main risks for Hangzhou Tigermed Consulting Co., Ltd include economic downturns that could reduce pharmaceutical R&D spending, increased competition from other CROs, changes in regulatory requirements that could increase compliance costs, and data breaches and cybersecurity risks that could damage the company's reputation. Additionally, the company's reliance on the Chinese market exposes it to political and economic risks. Investors should carefully consider these risks before investing in HNGZY. The company's OTC listing also introduces additional risks related to liquidity and regulatory oversight.
What are the key factors to evaluate for HNGZY?
Evaluating HNGZY involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Comprehensive service offerings spanning preclinical to post-marketing. Primary risk to monitor: Economic downturns could reduce pharmaceutical R&D spending. This is not financial advice.
How frequently does HNGZY data refresh on this page?
HNGZY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HNGZY's recent stock price performance?
Recent price movement in Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive service offerings spanning preclinical to post-marketing. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HNGZY overvalued or undervalued right now?
Determining whether Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HNGZY?
Before investing in Hangzhou Tigermed Consulting Co., Ltd. (HNGZY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.
- AI analysis is pending and may provide additional insights.